Bavarian Nordic - Asset Resilience Ratio
Bavarian Nordic (BAVA) has an Asset Resilience Ratio of 5.84% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Bavarian Nordic (BAVA) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Bavarian Nordic's Asset Resilience Ratio has changed over time. See Bavarian Nordic shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Bavarian Nordic's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Bavarian Nordic.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 0% |
| Short-term Investments | Dkr884.93 Million | 5.84% |
| Total Liquid Assets | Dkr884.93 Million | 5.84% |
Asset Resilience Insights
- Limited Liquidity: Bavarian Nordic maintains only 5.84% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bavarian Nordic Industry Peers by Asset Resilience Ratio
Compare Bavarian Nordic's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Bavarian Nordic (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Bavarian Nordic.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.83% | Dkr551.54 Million ≈ $86.29 Million |
Dkr14.41 Billion ≈ $2.25 Billion |
+1.11pp |
| 2023-12-31 | 2.72% | Dkr390.25 Million ≈ $61.06 Million |
Dkr14.35 Billion ≈ $2.25 Billion |
-15.60pp |
| 2022-12-31 | 18.32% | Dkr2.27 Billion ≈ $355.12 Million |
Dkr12.39 Billion ≈ $1.94 Billion |
-7.53pp |
| 2021-12-31 | 25.85% | Dkr3.12 Billion ≈ $488.90 Million |
Dkr12.09 Billion ≈ $1.89 Billion |
+10.05pp |
| 2020-12-31 | 15.80% | Dkr1.38 Billion ≈ $216.56 Million |
Dkr8.76 Billion ≈ $1.37 Billion |
+13.32pp |
| 2019-12-31 | 2.48% | Dkr174.82 Million ≈ $27.35 Million |
Dkr7.05 Billion ≈ $1.10 Billion |
-64.51pp |
| 2018-12-31 | 66.99% | Dkr2.05 Billion ≈ $320.82 Million |
Dkr3.06 Billion ≈ $478.91 Million |
-6.34pp |
| 2017-12-31 | 73.33% | Dkr2.31 Billion ≈ $361.72 Million |
Dkr3.15 Billion ≈ $493.26 Million |
+35.75pp |
| 2016-12-31 | 37.58% | Dkr1.06 Billion ≈ $166.04 Million |
Dkr2.82 Billion ≈ $441.79 Million |
+2.76pp |
| 2015-12-31 | 34.82% | Dkr692.72 Million ≈ $108.38 Million |
Dkr1.99 Billion ≈ $311.23 Million |
+4.02pp |
| 2014-12-31 | 30.80% | Dkr581.35 Million ≈ $90.96 Million |
Dkr1.89 Billion ≈ $295.28 Million |
+18.05pp |
| 2013-12-31 | 12.76% | Dkr185.28 Million ≈ $28.99 Million |
Dkr1.45 Billion ≈ $227.21 Million |
+0.00pp |
| 2012-12-31 | 12.76% | Dkr196.36 Million ≈ $30.72 Million |
Dkr1.54 Billion ≈ $240.82 Million |
-3.02pp |
| 2011-12-31 | 15.78% | Dkr311.92 Million ≈ $48.80 Million |
Dkr1.98 Billion ≈ $309.25 Million |
+9.72pp |
| 2010-12-31 | 6.06% | Dkr88.87 Million ≈ $13.90 Million |
Dkr1.47 Billion ≈ $229.54 Million |
-2.13pp |
| 2009-12-31 | 8.19% | Dkr104.05 Million ≈ $16.28 Million |
Dkr1.27 Billion ≈ $198.87 Million |
-13.86pp |
| 2008-12-31 | 22.05% | Dkr373.54 Million ≈ $58.44 Million |
Dkr1.69 Billion ≈ $265.08 Million |
+9.07pp |
| 2007-12-31 | 12.98% | Dkr224.80 Million ≈ $35.17 Million |
Dkr1.73 Billion ≈ $270.99 Million |
-11.26pp |
| 2006-12-31 | 24.24% | Dkr231.32 Million ≈ $36.19 Million |
Dkr954.42 Million ≈ $149.33 Million |
+12.01pp |
| 2005-12-31 | 12.23% | Dkr113.52 Million ≈ $17.76 Million |
Dkr928.56 Million ≈ $145.28 Million |
-6.47pp |
| 2004-12-31 | 18.70% | Dkr112.57 Million ≈ $17.61 Million |
Dkr602.10 Million ≈ $94.20 Million |
-1.98pp |
| 2003-12-31 | 20.68% | Dkr88.76 Million ≈ $13.89 Million |
Dkr429.17 Million ≈ $67.15 Million |
+15.95pp |
| 2002-12-31 | 4.74% | Dkr15.04 Million ≈ $2.35 Million |
Dkr317.70 Million ≈ $49.71 Million |
-28.91pp |
| 2001-12-31 | 33.65% | Dkr20.82 Million ≈ $3.26 Million |
Dkr61.87 Million ≈ $9.68 Million |
-4.56pp |
| 2000-12-31 | 38.21% | Dkr31.98 Million ≈ $5.00 Million |
Dkr83.69 Million ≈ $13.09 Million |
-- |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more